POSB211 Is an Early Access Program for an Oncology Drug an Asset in the French Pricing and Reimbursement Pathway?
Abstract
Authors
F Cogez M Gervais SC Cardon I Kachaner M Bougeois
F Cogez M Gervais SC Cardon I Kachaner M Bougeois
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now